Tazeen Ahmad
Stock Analyst at B of A Securities
(3.67)
# 794
Out of 5,090 analysts
214
Total ratings
50.32%
Success rate
6.59%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $27.82 | +7.86% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $26 → $29 | $22.05 | +31.55% | 9 | Oct 20, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $45.35 | +16.87% | 1 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $464.56 | +11.93% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $100.48 | +3.50% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $208.09 | +10.53% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $916.31 | -3.20% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $22.81 | -29.86% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $77.83 | -2.35% | 19 | Aug 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $27 | $26.59 | +1.56% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $95.99 | +39.60% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.06 | +58.10% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $106.01 | -10.38% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.86 | +90.96% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $11.30 | -64.60% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $8.81 | -9.19% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $20.30 | +33.00% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $12.62 | +121.96% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $96.20 | -27.23% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $11.21 | +256.82% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $153.75 | +16.42% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $16.39 | +34.23% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $5.33 | -43.71% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $9.93 | +51.10% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $8.88 | -77.46% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $36.60 | +107.65% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.52 | +121.48% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.11 | +442.99% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.44 | +20.58% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.54 | -43.50% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.54 | +289.61% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $18.39 | -18.43% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $191.83 | -68.72% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $4.37 | +266.55% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $177.89 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $13.09 | +2,191.83% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.29 | +293.87% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.97 | +100.25% | 6 | Oct 10, 2018 |
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $27.82
Upside: +7.86%
Apellis Pharmaceuticals
Oct 20, 2025
Maintains: Neutral
Price Target: $26 → $29
Current: $22.05
Upside: +31.55%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $45.35
Upside: +16.87%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $464.56
Upside: +11.93%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $100.48
Upside: +3.50%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $208.09
Upside: +10.53%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $916.31
Upside: -3.20%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $22.81
Upside: -29.86%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $77.83
Upside: -2.35%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $26.59
Upside: +1.56%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $95.99
Upside: +39.60%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $5.06
Upside: +58.10%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $106.01
Upside: -10.38%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.86
Upside: +90.96%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $11.30
Upside: -64.60%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $8.81
Upside: -9.19%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $20.30
Upside: +33.00%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $12.62
Upside: +121.96%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $96.20
Upside: -27.23%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $11.21
Upside: +256.82%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $153.75
Upside: +16.42%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $16.39
Upside: +34.23%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $5.33
Upside: -43.71%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.93
Upside: +51.10%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $8.88
Upside: -77.46%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $36.60
Upside: +107.65%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.52
Upside: +121.48%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.11
Upside: +442.99%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.44
Upside: +20.58%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.54
Upside: -43.50%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.54
Upside: +289.61%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $18.39
Upside: -18.43%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $191.83
Upside: -68.72%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $4.37
Upside: +266.55%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $177.89
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $13.09
Upside: +2,191.83%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.29
Upside: +293.87%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.97
Upside: +100.25%